Proceedings from the 2^ndNext Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

Authors

S. W. Canna
G. S. Schulert
A. De Jesus
A. Pickering
H. Brunner
M. Gadina
S. Levine
R. Goldbach-Mansky
B. Gottlieb, Zucker School of Medicine at Hofstra/Northwell
V. Delgaizo
+20 additional authors

Publication Date

2020

Journal Title

Pediatr Rheumatol Online J

Abstract

© 2020 The Author(s). For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.

Volume Number

18

Issue Number

Suppl 1

Pages

53

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

General Pediatrics

PMID

32664935

DOI

10.1186/s12969-020-00444-7